---
document_datetime: 2024-03-20 17:04:21
document_pages: 28
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/esbriet-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: esbriet-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 15.5828137
conversion_datetime: 2025-12-27 20:53:36.965054
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Esbriet

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0081            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 19/03/2024                          |                                             | SmPC and PL                      |           |
| IA/0080              | A.7 - Administrative change - Deletion of manufacturing sites                                  | 15/06/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0074   | Extension of indication to include treatment of 'advanced' idiopathic pulmonary fibrosis (IPF) by   | 23/02/2023   | 24/03/2023   | SmPC and PL            | Please refer to Scientific Discussion 'Esbriet-H-C-2154-II- 0074'.   |
|-----------|-----------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|----------------------------------------------------------------------|
| N/0079    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)    | 17/03/2023   |              | PL                     |                                                                      |
| IA/0078   | B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s)               | 05/08/2022   | 24/03/2023   | SmPC, Labelling and PL |                                                                      |
| N/0077    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)    | 13/06/2022   | 24/03/2023   | Labelling and          |                                                                      |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            | PL                               |                                                                                                                                           |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0076            | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                             | 08/03/2022 | n/a        |                                  |                                                                                                                                           |
| IA/0075            | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                    | 25/02/2022 | n/a        |                                  |                                                                                                                                           |
| PSUSA/2435/ 202102 | Periodic Safety Update EU Single assessment - pirfenidone                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/10/2021 | 09/12/2021 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2435/202102. |
| IA/0073            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                        | 07/07/2021 | n/a        |                                  |                                                                                                                                           |
| II/0070            | Update of section 4.8 of the SmPC to revise the MeDRA frequency categories for some adverse drug reactions (ADR) and to combine the ADR 'anorexia' with the preferred term 'decreased appetite' based on a safety update report previously submitted in variation EMEA/H/C/2154/II/0021. The package leaflet is updated accordingly. Minor formatting changes were introduced in Annex II, IIIA and IIIB in the list of local representatives. C.I.4 - Change(s) in the SPC, Labelling or PL due to | 10/06/2021 | 09/12/2021 | SmPC, Annex II, Labelling and PL |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0071   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12/03/2021 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0066/G | This was an application for a group of variations. Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on drug-induced liver injury (DILI) subsequent to the latest PSUSA (EMEA/H/C/PSUSA/00002435/201902) and post- authorisation measure (EMEA/H/C/2154/LEG/015). The annex II and package leaflet (PL) are updated accordingly. The RMP version 10.2 has also been updated. In addition, the MAH took the opportunity to add in the PL information about sodium content in line with excipients guideline (EMA/CHMP/302620/2017) and to correct formatting, punctuation and spelling mistakes in the product information. Update of sections 4.4 and 4.8 of the SmPC in order to add a warning on hyponatraemia and to add hyponatraemia with a frequency 'uncommon' to the list adverse reactions subsequent to the latest PSUSA (EMEA/H/C/PSUSA/00002435/201902) and post- authorisation measure (EMEA/H/C/2154/LEG/015). The PL is updated accordingly. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the | 01/10/2020 | 16/11/2020 | SmPC, Annex II and PL | Drug-induced liver injury: Elevated transaminases have been commonly reported in patients treated with Esbriet. Uncommonly, elevations in AST and ALT were associated with concomitant bilirubin increases. Cases of severe drug- induced liver injury, including isolated cases with fatal outcome, have been reported post-marketing. Liver function tests (ALT, AST and bilirubin) should be performed prior to the initiation of treatment with Esbriet, and subsequently at monthly intervals for the first 6 months and then every 3 months thereafter. In addition, prompt clinical evaluation and measurement of liver function tests should be performed in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. In the event of significant elevation of liver aminotransferases or clinical signs and symptoms of liver injury, the dose of Esbriet should be adjusted or treatment discontinued according to the guidelines listed below. For patients with confirmed elevations in ALT, AST or bilirubin during treatment, the following dose adjustments may be necessary. Discontinuation of other medicines associated with liver toxicity should be considered. Hyponatraemia has been reported in patients treated with Esbriet. As the symptoms of hyponatraemia may be subtle and masked by the presence of concomitant morbidities, regular monitoring of the relevant laboratory parameters is |

<div style=\"page-break-after: always\"></div>

|                    | assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     | recommended, especially in the presence of evocative signs and symptoms such as nausea, headache or dizziness. For more information, please refer to the Summary of Product Characteristics.   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2435/ 202002 | Periodic Safety Update EU Single assessment - pirfenidone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 01/10/2020 | n/a | PRAC Recommendation - maintenance                                                                                                                                                              |
| IA/0068/G          | This was an application for a group of variations. B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - | 04/06/2020 | n/a |                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|           | Deletion of certificates (in case multiple certificates exist per material) B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)                                                                                                                                                                                                                   |            |            |      |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|
| IB/0065   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                   | 16/01/2020 | n/a        |      |
| IB/0064/G | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                       | 09/01/2020 | 16/11/2020 | SmPC |
| IB/0063/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new | 19/12/2019 | n/a        |      |

<div style=\"page-break-after: always\"></div>

|                    | specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting   |            |            |                  |                                                                                                                                           |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2435/ 201902 | Periodic Safety Update EU Single assessment - pirfenidone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 19/09/2019 | 11/11/2019 | SmPC and PL      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2435/201902. |
| N/0060             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 21/03/2019 | 09/04/2019 | Labelling and PL |                                                                                                                                           |
| IA/0061/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 12/03/2019 | n/a        |                  |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                    | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                   |            |            |    |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| IB/0059            | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                     | 19/12/2018 | n/a        |    |                                   |
| IB/0058/G          | This was an application for a group of variations. B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.f.1.e - Stability of FP - Change to an approved stability protocol | 04/10/2018 | n/a        |    |                                   |
| PSUSA/2435/ 201802 | Periodic Safety Update EU Single assessment - pirfenidone                                                                                                                                                                                                                                                                                                                                | 06/09/2018 | n/a        |    | PRAC Recommendation - maintenance |
| N/0057             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                         | 09/08/2018 | 09/04/2019 | PL |                                   |
| IG/0949/G          | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting                                                                                                                                                                                                     | 04/06/2018 | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

|             | material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)                                                                                                                                                                                 |            |            |                        |                                                                                                                                                                                                                                                                                                                                         |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0051     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                            | 07/05/2018 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                         |
| IAIN/0053/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 17/04/2018 | 09/04/2019 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                         |
| T/0052      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                      | 16/03/2018 | 04/04/2018 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                         |
| SW/0054     | Post Authorisation Safety Study results - EMEA/H/C/PSR/S/0011                                                                                                                                                                                                                                                                                                                                                                                            | 14/12/2017 | 08/02/2018 | Annex II               | The prospective observational registry submitted by the MAH complies with their obligation to conduct a prospective observational registry to evaluate long-term safety in a real-world setting, as imposed during the marketing authorisation of Esbriet (pirfenidone) procedure EMEA/H/C/002154. Therefore, in view of available data |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                            |            |            |             | regarding the PASS final study report, the PRAC considered that changes to the conditions of the marketing authorisation were warranted.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0887 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                           | 29/01/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0049 | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                       | 18/12/2017 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0043 | Update of sections 4.2 and 5.2 of the SmPC in order to update dosing recommendations and pharmacokinetic information for patients with renal impairment based on the totality of data from clinical studies; the Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/10/2017 | 08/12/2017 | SmPC and PL | No dose adjustment is necessary in patients with mild renal impairment. Esbriet should be used with caution in patients with moderate (CrCl 30-50 ml/min) renal impairment. Esbriet therapy should not be used in patients with severe renal impairment (CrCl <30 ml/min) or end stage renal disease requiring dialysis. The use of pirfenidone is contraindicated in patients with severe renal impairment (CrCl <30ml/min) or end stage renal disease requiring dialysis. Approximately 70-80% of pirfenidone is metabolised via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6, and 2E1. In vitro data indicate some pharmacologically relevant activity of the major metabolite (5 carboxy-pirfenidone) at concentrations in excess of peak plasma concentrations in IPF patients. This may become clinically relevant in patients with moderate renal impairment where plasma exposure to 5 carboxy-pirfenidone is increased. The mean exposure to 5 carboxy-pirfenidone was significantly higher in the |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                        | moderate and severe renal impairment groups than in the group with normal renal function.   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------|
| PSUSA/2435/ 201702 | Periodic Safety Update EU Single assessment - pirfenidone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 28/09/2017 | n/a        |                        | PRAC Recommendation - maintenance                                                           |
| IA/0047            | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 18/08/2017 | n/a        |                        |                                                                                             |
| IB/0046/G          | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished | 26/06/2017 | 08/12/2017 | SmPC, Labelling and PL |                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.g.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supporting data B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes   |            |            |                        | product - Change in   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------|
| IA/0044/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                        | 24/05/2017 | n/a        |                        |                       |
| X/0035/G  | This was an application for a group of variations. Extension application to introduce a new pharmaceutical form associated with 3 new strengths                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 23/02/2017 | 24/04/2017 | SmPC, Labelling and PL |                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | (267mg, 534mg and 801mg film-coated tablets). In addition, the following manufacturing sites are also introduced for the currently approved 267mg hard capsules presentations (EU/1/11/667/001- 003): B.I.b.1.f - To add F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland, as an alternative site responsible for quality control of the active substance B.I.b.1.f - To add Synlab Umweltinstitut GmbH, St. Peter-Strasse 25, 4020 Linz, Austria, as an alternative site responsible for quality control of the active substance Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for   |            |     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0042 | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 11/04/2017 | n/a |

<div style=\"page-break-after: always\"></div>

|           | variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0041   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/02/2017 | n/a |
| II/0039   | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 15/12/2016 | n/a |
| IB/0040/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation | 18/10/2016 | n/a |

<div style=\"page-break-after: always\"></div>

| PSUSA/2435/ 201602   | Periodic Safety Update EU Single assessment - pirfenidone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 29/09/2016   | n/a        |             | PRAC Recommendation - maintenance   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------|
| IA/0038/G            | This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) | 01/08/2016   | 24/04/2017 | SmPC and PL |                                     |
| N/0036               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 04/05/2016   | 24/04/2017 | Labelling   |                                     |
| IG/0667/G            | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved                                                                                                                                                                             | 08/04/2016   | n/a        |             |                                     |

<div style=\"page-break-after: always\"></div>

|           | manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |            |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------|
| IB/0033/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - of in-process limits | 14/01/2016 | n/a | Tightening |
| IA/0032/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or                                                                                                                                                                                                                                                                                                                                                                                                                  | 16/10/2015 | n/a |            |

<div style=\"page-break-after: always\"></div>

|                    | manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                            |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2435/ 201502 | Periodic Safety Update EU Single assessment - pirfenidone                                                                                                                                                                                                                                       | 10/09/2015 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                 |
| R/0029             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                         | 23/07/2015 | 08/09/2015 | SmPC, Annex II, Labelling and PL | Based on the review of available information, the CHMP is of the opinion that the quality, safety and efficacy of Esbriet continues to be adequately and sufficiently demonstrated and considers that the benefit/risk profile of this medicinal product continues to be favourable. The product information has been updated to bring it in line with new QRD template. The CHMP recommends that the renewal be granted with unlimited validity. |
| IAIN/0031          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                 | 30/07/2015 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IAIN/0028/G        | This was an application for a group of variations. B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings B.II.b.2.c.1 - Change to importer, batch release | 07/05/2015 | 08/09/2015 | SmPC, Annex II and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                    | arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |            |                        |                                                                                           |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------|
| PSUSA/2435/ 201408 | Periodic Safety Update EU Single assessment - pirfenidone                                                                                                                                                                                                                                                                                                                                                                      | 12/03/2015 | n/a        |                        | PRAC Recommendation - maintenance                                                         |
| T/0027             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                            | 26/01/2015 | 12/02/2015 | SmPC, Labelling and PL | Transfer of Marketing Authorisation from InterMune UK Ltd. to Roche Registration Limited. |
| IAIN/0026          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                | 08/01/2015 | n/a        |                        |                                                                                           |
| IB/0024/G          | This was an application for a group of variations. B.II.e.5.z - Change in pack size of the finished product - Other variation B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s) B.II.a.3.a.1 - Changes in the composition (excipients) of the finished product - Changes in components of the flavouring or colouring system - Addition , deletion or replacement                          | 18/12/2014 | 12/02/2015 | SmPC, Labelling and PL |                                                                                           |

<div style=\"page-break-after: always\"></div>

|             | B.II.e.5.z - Change in pack size of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0025      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                       | 03/12/2014 | 12/02/2015 | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0021     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                      | 23/10/2014 | 12/02/2015 | SmPC and PL | In this variation sections 4.8 and 5.1 of the SmPC have been updated with safety and efficacy information based on the results of three studies ASCEND/PIPF-016, PIPF-012 and PIPF-002. The efficacy data provided from study PIPF- 016 (Phase 3 randomized, double-blind, placebo-controlled ), as well as the new pooling of the 52 week efficacy data have further demonstrated the efficacy of pirfenidone in IPF, especially with regards rate of FVC decline, 6MWT performance and mortality data. In addition, the safety update from the ongoing open label studies (PIPF-002 and 012) as well as the safety data from PIPF-016 have allowed the company to further refine the adverse event profile over long term use. |
| IAIN/0022/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV and/or QPPV contact details and/or back-up procedure C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) in the safety database and/or major contractual arrangements for the fulfilment of PhV obligations, and/or change of the site undergoing PhV activities | 29/09/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the PhV system                                                                                                                                                                                                                                                                                                    |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0020 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                   | 11/09/2014 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0016   | Update of section 4.8 of the SmPC to include 'agranulocytosis' as a rare event as a result of post marketing surveillance. Update of section 4.3, 4.4 and 4.8 of the SmPC with information on the risk of angioedema. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                  | 22/05/2014 | 27/06/2014 | SmPC and PL | Update of Section 4.8 of the SmPC to add 'agranulocytosis' following a spontaneous case report received by the MAH following post-marketing data. Update following parallel PRAC outcome PSUR 5 assessment of SmPC section 4.3 of the SmPC to include a contraindication in patients who have previously experienced angioedema with pirfenidone, update of section 4.4 to add a warning on the risk of angioedema and the need for patients who develop signs or symptoms of angioedema following administration of pirfenidone to discontinue treatment and update of section 4.8 of the SmPC to add 'angioedema' with a frequency |
| PSUV/0018 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                   | 10/04/2014 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0014/G | This was an application for a group of variations. B.I.a.1.g - to add an alternative manufacturer of the active substance (pirfenidone) B.I.a.1.f - to add an alternative site for microbiological testing of pirfenidone manufactured at the alternative site B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is | 20/02/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|             | not supported by an ASMF and requires significant update to the relevant AS section in the dossier B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                      |            |            |             |                                                                                                                                   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0019/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) in the safety database and/or major contractual arrangements for the fulfilment of PhV obligations, and/or change of the site undergoing PhV activities C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the PhV system | 09/01/2014 | n/a        |             |                                                                                                                                   |
| PSUV/0017   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24/10/2013 | 17/12/2013 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0017. |
| IB/0013/G   | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-                                                                                                                                               | 08/11/2013 | n/a        |             |                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|             | control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                              |            |            |                                  | release, batch   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------|
| IA/0015     | B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 04/10/2013 | n/a        |                                  |                  |
| IAIN/0012/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) in the safety database and/or major contractual arrangements for the fulfilment of PhV obligations, and/or change of the site undergoing PhV activities C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) | 21/08/2013 | 17/12/2013 | SmPC, Annex II, Labelling and PL |                  |

<div style=\"page-break-after: always\"></div>

|           | to the DDPS that does not impact on the operation of the PhV system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0011/G | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings                                                                                                                                                                                                                                                                                       | 25/07/2013 | 17/12/2013 | SmPC and PL                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0010   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/06/2013 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0008   | Update of sections 4.5 and 5.2 of the SmPC with results of the ciprofloxacin DDI study (PIPF-017) to reflect the potential for drug interactions with CYP1A2 inhibitors, including a recommendation for caution when Esbriet is used in patients treated with moderate or strong and selective inhibitors of CYP1A2. Additionally, update of the PI with minor editorial changes and in accordance with the latest QRD template and update of the PL to update the information regarding several local representatives. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article | 25/04/2013 | 17/12/2013 | SmPC, Annex II, Labelling and PL | A number of in vitro-in vivo extrapolations (IVIVE) allowed for the modelling of potential changes in substrate drug AUC values secondary to drug-drug interaction studies (DDI) and indicate that strong and selective inhibitors of CYP1A2 have the potential to increase the exposure to pirfenidone by approximately 2 to 4-fold. Esbriet should be used with caution in patients treated with moderate or strong and selective inhibitors of CYP1A2. If concomitant use of Esbriet with a strong and selective inhibitor of CYP1A2 cannot be avoided the dose of Esbriet should be reduced and patients should be closely monitored for emergence of adverse reactions associated with Esbriet therapy. The treatment should be discontinued if necessary. |

<div style=\"page-break-after: always\"></div>

|             | or amendments to reflect a Core SPC - with new additional data submitted by the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                 | 45/46, Change(s) MAH   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------|
| IA/0009/G   | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other | 09/04/2013 | n/a        |                 | variation              |
| IAIN/0007/G | This was an application for a group of variations. B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a                                                                                                                                                                                                                                                                                                                                                                                                       | 18/06/2012 | 29/10/2012 | Annex II and PL |                        |

<div style=\"page-break-after: always\"></div>

| manufacturing site for the site B.II.b.2.a - Change to batch and quality control testing or addition of a site where takes place B.II.b.2.a - Change to batch and quality control testing or addition of a site where takes place B.III.1.b.2 - Submission TSE Certificate of suitability starting material/reagent/intermediate/or from a new or an already B.III.1.b.2 - Submission TSE Certificate of suitability starting material/reagent/intermediate/or from a new or an already B.III.1.b.2 - Submission TSE Certificate of suitability starting material/reagent/intermediate/or from a new or an already B.III.1.b.2 - Submission TSE Certificate of suitability starting material/reagent/intermediate/or from a new or an already B.III.1.b.2 - Submission TSE Certificate of suitability starting material/reagent/intermediate/or from a new or an already B.III.1.b.2 - Submission   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|             | excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer   |            |            |                        | starting material/reagent/intermediate/or   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------|
| IAIN/0006/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                             | 19/01/2012 | 02/03/2012 | SmPC, Labelling and PL |                                             |
| N/0005      | Inclusion of the list of local representatives in the Package Leaflet. The MAH also took the opportunity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 01/12/2011 | 02/03/2012 | Labelling and PL       |                                             |

<div style=\"page-break-after: always\"></div>

|           | make minor linguistic changes to the Danish, Norwegian, Icelandic and Swedish product change in labelling or package leaflet not with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                        | to Finnish, information. Minor connected   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------|
| IA/0004/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing | 09/09/2011 | n/a        |                        | takes place                                |
| IA/0003   | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                               | 05/08/2011 | 05/08/2011 | SmPC, Labelling and PL |                                            |
| IA/0002/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 04/05/2011 | n/a        |                        |                                            |

<div style=\"page-break-after: always\"></div>

|         | C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system   |            |     |                        |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|
| IA/0001 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 20/04/2011 | n/a | SmPC, Labelling and PL |